



# Hippo Signaling: Emerging Pathway in Stress-Related Psychiatric Disorders?

Jens Stepan<sup>1</sup>, Elmira Anderzhanova<sup>2</sup> and Nils C. Gassen<sup>2\*</sup>

<sup>1</sup> Department Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany, <sup>2</sup> Clinic and Polyclinic of Psychiatry and Psychotherapy, Bonn University Clinic, Bonn, Germany

## OPEN ACCESS

### Edited by:

Naguib Mechawar,  
McGill University, Canada

### Reviewed by:

Emmanuel Moyses,  
Université de Tours, France  
Antoine Besnard,  
Harvard Medical School,  
United States

### \*Correspondence:

Nils C. Gassen  
nils.gassen@ukbonn.de

### Specialty section:

This article was submitted to  
Molecular Psychiatry,  
a section of the journal  
Frontiers in Psychiatry

**Received:** 14 October 2018

**Accepted:** 06 December 2018

**Published:** 21 December 2018

### Citation:

Stepan J, Anderzhanova E and  
Gassen NC (2018) Hippo Signaling:  
Emerging Pathway in Stress-Related  
Psychiatric Disorders?  
Front. Psychiatry 9:715.  
doi: 10.3389/fpsy.2018.00715

Discovery of the Hippo pathway and its core components has made a significant impact on our progress in the understanding of organ development, tissue homeostasis, and regeneration. Upon diverse extracellular and intracellular stimuli, Hippo signaling regulates stemness, cell proliferation and apoptosis by a well-conserved signaling cascade, and disruption of these systems has been implicated in cancer as well as metabolic and neurodegenerative diseases. The central role of Hippo signaling in cell biology also results in prominent links to stress-regulated pathways. Genetic variations, epigenetically provoked upregulation of Hippo pathway members and dysregulation of cellular processes implicated in learning and memory, are linked to an increased risk of stress-related psychiatric disorders (SRPDs). In this review, we summarize recent findings, supporting the role of Hippo signaling in SRPDs by canonical and non-canonical Hippo pathway interactions.

**Keywords:** hippo pathway, KIBRA, psychophysiological stress, synaptic plasticity, glucocorticoids, GPCRs

## INTRODUCTION

When the Hippo pathway was first discovered in *Drosophila*, it appeared as a linear kinase cascade highly relevant for proliferation and homeostasis, because deletion of core component genes resulted in an uncontrolled growth of multiple tissues (1, 2). Subsequent research identified mammalian orthologs of Hippo components and additional kinases, transcription factors and various adapter proteins directly or indirectly involved in Hippo signaling, providing a complex molecular network with strong regulatory effects on development, homeostasis, and regeneration (3–5). Upstream activators of the Hippo pathway include G-protein-coupled receptors (GPCR), integrins, and cell-cell adhesion factors, stress-reactive glucocorticoid hormones, metabolism-regulating hormones, growth factors, and mitogens (6).

Dysregulated Hippo signaling is associated with various cancers and a wide range of metabolic, cardiovascular, neurodevelopmental, and neurodegenerative diseases (3, 7). Regulators of Hippo pathway are expressed in the adults' brain suggesting their implementation in normal brain performance. Recent research further extends the Hippo signaling network and its potential to be therapeutically harnessed based on genetic association studies linking Hippo pathway members to stress-related-psychiatric disorders (SRPDs) (8–11). Key molecular and cellular processes that are thought to be involved in the pathophysiology of SPRDs are modulated by Hippo pathway members. Furthermore, various proteins of the Hippo signaling pathway are linked via the GR, GPCRs, Wnt-signaling and other pathways to stress-regulated signaling cascades (12–16).

In this review we highlight emerging evidence of an interaction between Hippo signaling and the stress axis and suggest how this novel link may correlate with the genesis of SRPDs.

## THE HIPPO PATHWAY IN MAMMALS AND ITS CANONICAL ACTIVATION

The regulatory endpoints of the Hippo pathway are the two homologous transcriptional co-activators, yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) (3, 7) (**Figure 1**). YAP and TAZ are widely expressed throughout the brain and non-neuronal tissues especially during embryogenesis<sup>1</sup> In adult humans YAP is expressed in the subventricular zone of the lateral ventricle and subgranular zone of the dentate gyrus, the regions providing neurogenesis in mammalian brains. Weak immunostaining was found in the prefrontal cortex of humans (17). YAP expresses in the midbrain, possibly, to protect dopaminergic neurons from degeneration (18). TAZ expression appears to contribute to brain mitochondrial respiration, the function of hippocampal neurons and glia, and modulates cognitive abilities in mice (19). It is of note that Hippo pathway activity is retained in the adult hippocampus. A role of the hippocampus in neurogenesis and stress resilience (20), denote the Hippo pathway as a target for biomarker discovery and therapeutic interventions in SRPDs.

The regulation of YAP and TAZ is governed by two major protein kinase complexes, the mammalian Sterile 20-like kinases 1 and 2 (MST1/2), and the large tumor suppressor homolog LATS1/2 and their direct interaction partners SAV1 (MST1/2) and MOB1A/MOB1B (LATS1/2). Activation of MST1/2 and LATS1/2 causes phosphorylation of YAP/TAZ. Phospho-YAP/TAZ is either degraded or sequestered in the cytoplasm by the 14-3-3 protein, whereas after inactivation of the upstream kinase cascade dephosphorylated YAP/TAZ translocate to the nucleus. AJUBA antagonizes YAP phosphorylation and therefore prevents its activation. Through association with various transcription factors, like the TEAD family transcription factors (TEAD1-4), YAP/TAZ initiates transcription of several genes mainly involved in the regulation of development, homeostasis, and regeneration (3, 7) (**Figure 1**). This core-signaling cascade is activated/ inactivated by multiple stimuli and modulated by various post-translational modifications or through hetero complex re-organization, e.g., NF2 (Merlin) inhibits LATS through phosphorylation (3, 7) (**Figure 1**). Although, YAP and TAZ are primarily controlled at the level of their nuclear accumulation (nucleocytoplasmic shuttling), it is incompletely elucidated if nuclear entry occurs passively (diffusion), if it is a mediated process, or a combination of both (21). In a recent report mechanical forces have been shown to increase the permeability of the nuclear pore thereby facilitating the nuclear accumulation of YAP (22), whereas another study identified a nuclear localization sequence (NLS) and a nuclear export sequence (NES) for TAZ (21). Moreover 14-3-3 protein

and TEAD family members have been proposed to be cytosolic and nuclear “retention factors,” respectively (21).

## NON-CANONICAL REGULATION OF HIPPO SIGNALING BY PSYCHOPHYSIOLOGICAL STRESS

Accumulating evidence suggests that the core complexes and accessory proteins of the Hippo pathway can be modulated by molecular pathways that play a fundamental role in stress signaling. The non-canonical regulation of the Hippo pathway with regard to SRPDs will be the focus of the following chapter.

## GLUCOCORTICOIDS IMPACT ON HIPPO PATHWAY


Release of glucocorticoids (GCs), such as cortisol, from the adrenal glands, is the final stage of hypothalamic-pituitary-adrenal (HPA) axis activation during emotionally stressful experiences [psychophysiological stress, depicted as “stress” throughout the manuscript, (23)]. GCs belong to the class of steroid hormones and act via specialized nuclear receptors to adapt behavior to a constantly changing environment. Despite the critical role that stress plays for body homeostasis, it is widely implicated in the onset of SRPDs (23). Sorrentino and colleagues described a molecular cascade that links glucocorticoid signaling to YAP regulation. In an interdisciplinary approach the researchers show, that the activation of glucocorticoid receptors (GRs) results in elevated YAP protein levels, its translocation to the nucleus and subsequently to enhanced transcriptional activity. Fibronectin was identified as a target of the GR. Increased fibronectin expression stimulates the focal adhesion-Src pathway, which in turn activates cytoskeleton-dependent YAP activation providing a direct link between the stress-hormone axis and Hippo signaling (24).

## GPCRS AND HIPPO PATHWAY IN SRPDs AND RELATED PSYCHOPATHOLOGIES

### GPCR Signaling

Extracellular signals act on synapses to drive spine morphogenesis and synaptic plasticity. Among multiple classes of receptors G protein-coupled receptors (GPCRs) are the working horses of neuronal communication. Overexpression or exogenous stimulation of a variety of GPCRs corresponds to Hippo pathway activity. Serotonin 5-HT<sub>4</sub>, adrenergic  $\alpha$ 1B, metabotropic glutamate mGlu<sub>2</sub>, and adenosine A<sub>1</sub>A receptors are directly mediating neuronal transmission in the brain and are shown to contribute to stress-related abnormalities in mammals (25–29). These receptors, which are linked to brain-body crosstalk (LPA receptors, purinergic receptors, muscarinic acetylcholine receptor M<sub>1</sub>, angiotensin II receptor, free fatty acid receptor 1, platelet-activating factor receptor, thromboxane A<sub>2</sub>, frizzled homolog D<sub>4</sub>, complement component 3a receptor 1, estrogen receptor 1, opioid receptor  $\Delta$ 1, secretin receptor, thyroid-stimulating hormone receptor, gastrin-releasing peptide

<sup>1</sup>Mouse Brain Atlas. <http://mousebrain.org/genesearch.html>



receptor, melanocortin receptor 1, somatostatin receptor 1, prostaglandin E receptor 2, and bombesin-like receptor 3) affect both the Hippo-YAP and Hippo-TAZ signaling via activation of Rho GTPases (16).

In contrast, dopamine D1 and adrenergic  $\beta$ 2 receptors appear as a way for the selective inhibition of Hippo-YAP signaling. These GPCRs induce YAP phosphorylation mainly via cAMP and PKA (16).

Selective regulation of the Hippo-YAP signaling by 5-HT<sub>2B</sub> receptors activation has been shown in hepatocytes (30) and cardiomyocytes (31). These data suggest an effect of acute and chronic serotonin neurotransmission disturbance on Hippo signaling and provides a strong link between stress and related pathologies in peripheral organs. Although most available drugs to treat the symptoms of SRPDs (antidepressants) target serotonergic neurotransmission (32), a putative modulation of Hippo signaling by antidepressants remains a topic of future research.

## Wnt SIGNALING

Components of the Wnt pathway are transcriptional targets and therefore downstream targets for the Hippo pathway (13–15). The upstream influence of the canonical Wnt/ $\beta$ -catenin signaling on the Hippo pathway has been described recently (12). Consequently, a dynamical interaction in the presence of Wnt YAP/TAZ is released from the destruction complex, escaping degradation in the cytoplasm. In absence of Wnt the YAP/TAZ-dependent  $\beta$ -TrCP ( $\beta$ -transducin repeats-containing proteins)

recruitment allows  $\beta$ -catenin destruction (33). Notably, the  $\beta$ -TrCP-mediated  $\beta$ -catenin degradation is GSK3-dependent (34). GSK3 plays a critical role in the regulation of Wnt–Hippo interaction (14).

## CANONICAL HIPPO PATHWAY LINKS TO SRPDs


Multiple studies have shown a direct association between members of the hippo pathway and SRPDs. Most data comes from genetic studies that report an association of allelic variation in the KIBRA (KIDney and BRAin) gene with (episodic) memory performance, gray and white matter volume and differences in functional brain activity (35–41). Substitution of C for T in the 9th intron (rs17070145) of the KIBRA gene, was first linked to memory performance and functional brain activity in a genome-wide association study (35). However, the functional role of the gene is still unclear since replication of the first results has proven difficult and sometimes delivered contradicting results. In line with the initial results, the rs17070145-T allele has been associated with better episodic memory functioning (36–41). However, several other studies have either associated the absence of rs17070145-T with better memory performance (42, 43), or were unable to show any link of this Single Nucleotide Polymorphism (SNP) with cognitive capabilities (43–46). CLSTN2 (calsyntenin 2), another hippo pathway member (SNP rs6439886), is mainly localized in the postsynaptic compartment of excitatory neurons in brain regions

relevant for learning and memory like the medial temporal lobe (47), and has also been linked to memory performance by Passotiropoulos et al. (35) and in subsequent cohorts (48, 49). Another study, however, did not support the influence of the KIBRA SNP, with or without the CLSTN2 SNP, on longitudinal memory decline or hippocampal atrophy in older adults (44).

It has been speculated, that the lack of consensus across studies stem from age-related neuropathological changes on memory performance, which may interact with polymorphisms such as KIBRA and CLSTN2, the so-called “resource modulation hypothesis” (40, 44). Supporting evidence comes from studies taking age, increased risk for specific diseases and pre-existing diseases into account (9, 10, 46). Stickel et al. (40) report, that KIBRA results in decreased verbal memory performance and lower brain volumes in CC homozygotes compared to T carriers, particularly among older persons (40). In individuals with unipolar depression, Pantzar et al. (10) showed an interactive effect of KIBRA and CLSTN2 polymorphisms on memory performance, but not in older individuals without depression (10). They also found poorer episodic recall and recognition

performance in non-T carriers (10). In contrast, in patients with major depressive disorder, Liu et al. (9) found that rs17070145 associates with better memory performance in non-T carriers (9). In cognitively normal adults with different genetic risk of Alzheimer’s disease, based on their A $\beta$ -amyloid levels and apolipoprotein E (APOE)  $\epsilon$ 2/ $\epsilon$ 3/ $\epsilon$ 4 genotype, Porter et al. (46) reported faster rates of cognitive decline and hippocampal atrophy in individuals with higher A $\beta$ -amyloid levels and APOE  $\epsilon$ 4 + ve, that did not carry the rs17070145-T allele (46). Although this suggests that the exact role of the KIBRA, SNP rs17070145 in learning and memory is still unclear, further investment in understanding its well-established role in cognitive performance is essential to make progress from mechanism to disease in SRPDs.

Another association of two neighboring SNPs in the KIBRA gene in almost complete linkage disequilibrium, rs10038727, and rs4576167, with lifetime risk for post-traumatic stress disorder was described in two samples from African conflict regions (8). Carriers of the minor allele of both SNPs displayed a diminished disease risk (8). Nitric oxide synthase 1 adaptor





protein (NOS1AP) also known as carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein (CAPON) is an adaptor protein of the Hippo pathway and is encoded by the NOS1AP gene in humans (11, 50). CAPON is supposed to modulate glutamate neurotransmission via interaction with postsynaptic density (PSD) scaffolding proteins PSD93 and PSD95 (50). Xu et al. (11) showed an increased expression of CAPON in the prefrontal cortex in post-mortem tissue of patients with bipolar disorder (11).

## KIBRA AS POTENTIAL MEDIATOR OF SYNAPTIC STRESS EFFECTS

Accumulating evidence suggests that the scaffold protein expressed by the KIDney and BRAin gene [KIBRA; sometimes referred to as WW and C2 domain-containing protein 1 (WWC1)], is critical for synaptic plasticity, the cellular mechanism thought to underlie learning and memory (51–56). Although it has not yet been demonstrated directly, KIBRA is a potential candidate to, at least partially, mediate the well-established stress effects on synaptic plasticity and cognitive performance (57, 58).

KIBRA is predominantly expressed in the kidney and the brain, in particular in structures important for learning and memory like the hippocampus, cortex, cerebellum, and hypothalamus (59, 60). In neuronal cells, KIBRA has a somatodendritic staining pattern with enrichment in perinuclear regions and the postsynaptic density (PSD) (54, 59). Previous studies have shown that KIBRA has various binding partners, mainly mediated by the two N-terminal WW domains, a glutamic acid-rich motif and motifs for binding atypical PKC and PDZ domains (54, 56, 61). This includes the postsynaptic proteins dendrin and synaptopodin, postsynaptic  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPA receptors, the main fast stimulatory receptor of the neurotransmitter glutamate), and the atypical protein kinase C (PKC) isoform protein kinase M $\zeta$  (PKM $\zeta$ ) (52, 53, 59, 60, 62, 63).

PKM $\zeta$  is brain specific and crucially involved in AMPA-receptor trafficking, a core mechanism of synaptic plasticity, and in the maintenance of long-term potentiation (LTP) in the hippocampus, which is thought to be the cellular correlate of learning and memory in mammals and involves AMPA and NMDA receptors of glutamate (51, 63–65). PKM $\zeta$  is colocalized with KIBRA especially in the hippocampus and dentate gyrus (65), and KIBRA knock-out mice exhibit reduced learning and memory performance in spatial memory tasks, accompanied by decreased PKM $\zeta$  levels (56). These results are in line with the observation that KIBRA associates with AMPARs and its partner

protein interacting with C-kinase 1 (PICK1), which has been shown to accelerate the rate of AMPAR subunit recycling to the postsynaptic membrane (53). Moreover, KIBRA knock out mice exhibit an impaired LTP and long-term depression (LTD) in the hippocampus and show deficits in contextual fear learning and memory (53).

Overexpression of KIBRA in neurons facilitates LTP, but prevents the induction of LTD, likely by an increased constitutive recycling of AMPARs. In contrast, knock down of KIBRA abolishes LTP and decreases AMPAR recycling supporting a role of KIBRA as a bidirectional regulator of synaptic plasticity in hippocampal neurons (52). In a recent study, Tracy et al. (55) show that memory loss and LTP impairment in a mouse model of Alzheimer's disease critically depends on reduced synaptic KIBRA levels accompanied by reduced activity-induced postsynaptic actin remodeling and AMPAR insertion, which can be rescued by promoting actin polymerization or by restoring KIBRA expression (55).

The WWC family comprises two additional highly similar paralogs, WWC2, and WWC3 (61). Although it has been speculated that WWC2 can balance WWC1 knock out (53), their role in brain function remains unclear.

## CONCLUSION

Strong evidence suggests that both, Hippo- and stress signaling are involved in the pathophysiology of SRPDs. However, the possible interaction between Hippo signaling and the stress hormone axis has been widely neglected so far. Especially KIBRA as a mediator of adaptive neuroplasticity that is directly linked to the stress hormone axis via GR-signaling might balance the reduced cognitive capabilities observed in most SRPDs (see **Figure 2**).

Although there are many important questions that remain unanswered (e.g., exact role of KIBRA in memory), pharmacological targeting of Hippo signaling might offer guidance for the development of novel prophylactic and therapeutic approaches to treat SRPDs more effectively.

## AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

## FUNDING

This work was partially funded by a NARSAD Young Investigator Award by Brain and Behavior Research Foundation, honored by P&S Fund (to NCG, Grant ID 25348).

## REFERENCES

- Justice RW, Zilian O, Woods DE, Noll M, Bryant PJ. The *Drosophila* tumor suppressor gene *warts* encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. *Genes Dev.* (1995) 9:534–46. doi: 10.1101/gad.9.5.534
- Xu T, Wang W, Zhang S, Stewart RA, Yu W. Identifying tumor suppressors in genetic mosaics: the *Drosophila* *lats* gene encodes a putative protein kinase. *Development* (1995) 121:1053–63.

3. Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. *Cell* (2015) 163:811–28. doi: 10.1016/j.cell.2015.10.044
4. Plouffe SW, Meng Z, Lin KC, Lin B, Hong AW, Chun JV, et al. Characterization of Hippo pathway components by gene inactivation. *Mol Cell*. (2016) 64:993–1008. doi: 10.1016/j.molcel.2016.10.034
5. Fu V, Plouffe SW, Guan KL. The Hippo pathway in organ development, homeostasis, and regeneration. *Curr Opin Cell Biol*. (2017) 49:99–107. doi: 10.1016/j.cob.2017.12.012
6. Misra JR, Irvine KD. The Hippo signaling network and its biological functions. *Annu Rev Genet*. (2018) 52:1–23. doi: 10.1146/annurev-genet-120417-031621
7. Ardestani A, Lupse B, Maedler K. Hippo signaling: key emerging pathway in cellular and whole-body metabolism. *Trends Endocrinol Metab*. (2018) 29:492–509. doi: 10.1016/j.tem.2018.04.006
8. Wilker S, Kolassa S, Vogler C, Lingenfelder B, Elbert T, Papassotiropoulos A, et al. The role of memory-related gene WWC1 (KIBRA) in lifetime posttraumatic stress disorder: evidence from two independent samples from African conflict regions. *Biol Psychiatry* (2013) 74:664–71. doi: 10.1016/j.biopsych.2013.02.022
9. Liu JJ, Lavebratt C, Lou F, Forsell Y. KIBRA genetic polymorphism and cognitive dysfunction in depression. *Psychiatry Res*. (2015) 226:405–6. doi: 10.1016/j.psychres.2015.01.012
10. Pantzar A, Laukka EJ, Atti AR, Papenberg G, Keller L, Graff C, et al. Interactive effects of KIBRA and CLSTN2 polymorphisms on episodic memory in old-age unipolar depression. *Neuropsychologia* (2014) 62:137–42. doi: 10.1016/j.neuropsychologia.2014.07.020
11. Xu B, Wratten N, Charych EI, Buyske S, Firestein BL, Brzustowicz LM. Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. *PLoS Med*. (2005) 2:e263. doi: 10.1371/journal.pmed.0020263
12. Azzolin L, Zancanato F, Bresolin S, Forcato M, Basso G, Biciato S, et al. Role of TAZ as mediator of Wnt signaling. *Cell* (2012) 151:1443–56. doi: 10.1016/j.cell.2012.11.027
13. Deng F, Peng L, Li Z, Tan G, Liang E, Chen S, et al. YAP triggers the Wnt/ $\beta$ -catenin signalling pathway and promotes enterocyte self-renewal, regeneration and tumorigenesis after DSS-induced injury. *Cell Death Dis*. (2018) 9:153. doi: 10.1038/s41419-017-0244-8
14. Huang W, Lv X, Liu C, Zha Z, Zhang H, Jiang Y, et al. The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCF $\beta$ -TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition. *J Biol Chem*. (2012) 287:26245–53. doi: 10.1074/jbc.M112.382036
15. Kim S, Jho E-H. Merlin, a regulator of Hippo signaling, regulates Wnt/ $\beta$ -catenin signaling. *BMB Rep*. (2016) 49:357–8. doi: 10.5483/BMBRep.2016.49.7.104
16. Yu F-X, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. *Cell* (2012) 150:780–91. doi: 10.1016/j.cell.2012.06.037
17. Orr BA, Bai H, Odia Y, Jain D, Anders RA, Eberhart CG. Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. *J Neuropathol Exp Neurol*. (2011) 70:568–77. doi: 10.1097/NEN.0b013e31821ff8d8
18. Zhang D, Yang S, Toledo EM, Gyllborg D, Saltó C, Carlos Villaescusa J, et al. Niche-derived laminin-511 promotes midbrain dopaminergic neuron survival and differentiation through YAP. *Sci Signal*. (2017) 10:14165. doi: 10.1126/scisignal.aal4165
19. Cole LK, Kim JH, Amoscato AA, Tyurina YY, Bayir H, Karimi B, et al. Aberrant cardiolipin metabolism is associated with cognitive deficiency and hippocampal alteration in tafazzin knockdown mice. *Biochim Biophys Acta Mol Basis Dis*. (2018) 1864:3353–67. doi: 10.1016/j.bbadis.2018.07.022
20. Levone BR, Cryan JF, O'Leary OF. Role of adult hippocampal neurogenesis in stress resilience. *Neurobiol Stress* (2015) 1:147–55. doi: 10.1016/j.ynstr.2014.11.003
21. Kofler M, Speight P, Little D, Di Ciano-Oliveira C, Szasz K, Kapus A. Mediated nuclear import and export of TAZ and the underlying molecular requirements. *Nat Commun*. (2018) 9:4966. doi: 10.1038/s41467-018-07450-0
22. Elosegui-Artola A, Andreu I, Beedle AEM, Lezamiz A, Uroz M, Kosmalska AJ, et al. Force triggers YAP nuclear entry by regulating transport across nuclear pores. *Cell* (2017) 171:1397–410 e14. doi: 10.1016/j.cell.2017.10.008
23. de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. *Nat Rev Neurosci*. (2005) 6:463–75. doi: 10.1038/nrn1683
24. Sorrentino G, Ruggeri N, Zannini A, Ingallina E, Bertolio R, Marotta C, et al. Glucocorticoid receptor signalling activates YAP in breast cancer. *Nat Commun*. (2017) 8:14073. doi: 10.1038/ncomms14073
25. Amigó J, Diaz A, Pilar-Cuellar F, Vidal R, Martín A, Compan V, et al. The absence of 5-HT4 receptors modulates depression- and anxiety-like responses and influences the response of fluoxetine in olfactory bulbectomized mice: adaptive changes in hippocampal neuroplasticity markers and 5-HT1A autoreceptor. *Neuropharmacology* (2016) 111:47–58. doi: 10.1016/j.neuropharm.2016.08.037
26. Cohen H, Zohar J, Kaplan Z, Arnt J. Adjunctive treatment with brexpiprazole and escitalopram reduces behavioral stress responses and increase hypothalamic NPY immunoreactivity in a rat model of PTSD-like symptoms. *Eur Neuropsychopharmacol*. (2018) 28:63–74. doi: 10.1016/j.euroneuro.2017.11.017
27. De Filippis B, Lyon L, Taylor A, Lane T, Burnet PWJ, Harrison PJ, et al. The role of group II metabotropic glutamate receptors in cognition and anxiety: Comparative studies in GRM2 $^{-/-}$ , GRM3 $^{-/-}$  and GRM2/3 $^{-/-}$  knockout mice. *Neuropharmacology* (2015) 89:19–32. doi: 10.1016/j.neuropharm.2014.08.010
28. Peterlik D, Flor PJ, Uschold-Schmidt N. The emerging role of metabotropic glutamate receptors in the pathophysiology of chronic stress-related disorders. *Curr Neuropharmacol*. (2016) 14:514–39. doi: 10.2174/1570159X13666150515234920
29. Vincenzi F, Ravani A, Pasquini S, Merighi S, Gessi S, Romagnoli R, et al. Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety. *Neuropharmacology* (2016) 111:283–92. doi: 10.1016/j.neuropharm.2016.09.015
30. Liu S, Miao R, Zhai M, Pang Q, Deng Y, Liu S, et al. Effects and related mechanisms of serotonin on malignant biological behavior of hepatocellular carcinoma via regulation of Yap. *Oncotarget* (2017) 8:47412–24. doi: 10.18632/oncotarget.17658
31. Kwon D, Kohar Y, Stafford N, Oceandy D. 176 Serotonin receptor 2b (5-ht2b) modulates cardiomyocyte proliferation by regulating the hippo pathway. *Heart* (2017) 103(Suppl. 5):A122.2–A122. doi: 10.1136/heartjnl-2017-311726.174
32. Stepan J, Hladky F, Uribe A, Holsboer F, Schmidt MV, Eder M. High-Speed imaging reveals opposing effects of chronic stress and antidepressants on neuronal activity propagation through the hippocampal trisynaptic circuit. *Front Neural Circ*. (2015) 9:70. doi: 10.3389/fncir.2015.00070
33. Wang Z, Ye J, Deng Y, Yan Z, Denduluri S, He T-C. Wnt versus Hippo: A balanced act or dynamic duo? *Genes Dis*. (2014) 1:127–8. doi: 10.1016/j.gendis.2014.09.001
34. MacDonald BT, Tamai K, He X. Wnt/ $\beta$ -Catenin signaling: components, mechanisms, and diseases. *Developmental Cell* (2009) 17:9–26. doi: 10.1016/j.devcel.2009.06.016
35. Papassotiropoulos A, Stephan DA, Huentelman MJ, Hoernldi FJ, Craig DW, Pearson JV, et al. Common Kibra alleles are associated with human memory performance. *Science* (2006) 314:475–8. doi: 10.1126/science.1129837
36. Almeida OP, Schwab SG, Lautenschlager NT, Morar B, Greenop KR, Flicker L, et al. KIBRA genetic polymorphism influences episodic memory in later life, but does not increase the risk of mild cognitive impairment. *J Cell Mol Med*. (2008) 12:1672–6. doi: 10.1111/j.1582-4934.2008.00229.x
37. Bates TC, Price JF, Harris SE, Marioni RE, Fowkes FG, Stewart MC, et al. Association of KIBRA and memory. *Neurosci Lett*. (2009) 458:140–3. doi: 10.1016/j.neulet.2009.04.050
38. Kauppi K, Nilsson LG, Adolfsson R, Eriksson E, Nyberg L. KIBRA polymorphism is related to enhanced memory and elevated hippocampal processing. *J Neurosci*. (2011) 31:14218–22. doi: 10.1523/JNEUROSCI.3292-11.2011
39. Witte AV, Kobe T, Kerti L, Rujescu D, Floel A. Impact of KIBRA polymorphism on memory function and the hippocampus in older adults. *Neuropsychopharmacology* (2016) 41:781–90. doi: 10.1038/npp.2015.203

40. Stickel A, Kawa K, Walther K, Glisky E, Richholt R, Huentelman M, et al. Age-Modulated Associations between KIBRA, Brain Volume, and Verbal Memory among Healthy Older Adults. *Front Aging Neurosci.* (2017) 9:431. doi: 10.3389/fnagi.2017.00431
41. Zlomuzica A, Preusser F, Roberts S, Woud ML, Lester KJ, Dere E, et al. The role of KIBRA in reconstructive episodic memory. *Mol Med.* (2018) 24:7. doi: 10.1186/s10020-018-0007-8
42. Nacmias B, Bessi V, Bagnoli S, Tedde A, Cellini E, Piccini C, et al. KIBRA gene variants are associated with episodic memory performance in subjective memory complaints. *Neurosci Lett.* (2008) 436:145–7. doi: 10.1016/j.neulet.2008.03.008
43. Wersching H, Guske K, Hasenkamp S, Hagedorn C, Schiwiek S, Jansen S, et al. Impact of common KIBRA allele on human cognitive functions. *Neuropsychopharmacology* (2011) 36:1296–304. doi: 10.1038/npp.2011.16
44. Boraxbekk CJ, Ames D, Kochan NA, Lee T, Thalamuthu A, Wen W, et al. Investigating the influence of KIBRA and CLSTN2 genetic polymorphisms on cross-sectional and longitudinal measures of memory performance and hippocampal volume in older individuals. *Neuropsychologia* (2015) 78:10–7. doi: 10.1016/j.neuropsychologia.2015.09.031
45. Need AC, Attix DK, McEvoy JM, Cirulli ET, Linney KN, Wagoner AP, et al. Failure to replicate effect of Kibra on human memory in two large cohorts of European origin. *Am J Med Genet Part B, Neuropsychiatr Genet.* (2008) 147B:667–8. doi: 10.1002/ajmg.b.30658
46. Porter T, Burnham SC, Dore V, Savage G, Bourgeat P, Begemann K, et al. KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE epsilon4-positive cognitively normal adults with high Abeta-amyloid burden. *Sci Rep.* (2018) 8:2034. doi: 10.1038/s41598-018-20513-y
47. Hintsch G, Zurlinden A, Meskenaite V, Steuble M, Fink-Widmer K, Kinter J, et al. The calyntenins—a family of postsynaptic membrane proteins with distinct neuronal expression patterns. *Mol Cell Neurosci.* (2002) 21:393–409. doi: 10.1006/mcne.2002.1181
48. Jacobsen LK, Picciotto MR, Heath CJ, Mencl WE, Gelernter J. Allelic variation of calyntenin 2 (CLSTN2) modulates the impact of developmental tobacco smoke exposure on mnemonic processing in adolescents. *Biol Psychiatry* (2009) 65:671–9. doi: 10.1016/j.biopsych.2008.10.024
49. Laukka EJ, Lovden M, Herlitz A, Karlsson S, Ferencz B, Pantzar A, et al. Genetic effects on old-age cognitive functioning: a population-based study. *Psychol Aging* (2013) 28:262–74. doi: 10.1037/a0030829
50. Jaffrey SR, Snowman AM, Eliasson MJ, Cohen NA, Snyder SH. CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. *Neuron* (1998) 20:115–24. doi: 10.1016/S0896-6273(00)80439-0
51. Huganir RL, Nicoll RA. AMPARs and synaptic plasticity: the last 25 years. *Neuron* (2013) 80:704–17. doi: 10.1016/j.neuron.2013.10.025
52. Heitz FD, Farinelli M, Mohanna S, Kahn M, Duning K, Frey MC, et al. The memory gene KIBRA is a bidirectional regulator of synaptic and structural plasticity in the adult brain. *Neurobiol Learn Mem.* (2016) 135:100–14. doi: 10.1016/j.nlm.2016.07.028
53. Makuch L, Volk L, Anggono V, Johnson RC, Yu Y, Duning K, et al. Regulation of AMPA receptor function by the human memory-associated gene KIBRA. *Neuron* (2011) 71:1022–9. doi: 10.1016/j.neuron.2011.08.017
54. Schneider A, Huentelman MJ, Kremerskothen J, Duning K, Spoelgen R, Nikolich K. KIBRA: a new gateway to learning and memory? *Front Aging Neurosci.* (2010) 2:4. doi: 10.3389/neuro.24.0042010
55. Tracy TE, Sohn PD, Minami SS, Wang C, Min SW, Li Y, et al. Acetylated tau obstructs KIBRA-mediated signaling in synaptic plasticity and promotes tauopathy-related memory loss. *Neuron* (2016) 90:245–60. doi: 10.1016/j.neuron.2016.03.005
56. Vogt-Eisele A, Kruger C, Duning K, Weber D, Spoelgen R, Pitzer C, et al. KIBRA (Kidney/BRAin protein) regulates learning and memory and stabilizes Protein kinase Mzeta. *J Neurochem.* (2014) 128:686–700. doi: 10.1111/jnc.12480
57. Sapolsky RM, Krey LC, McEwen BS. The neuroendocrinology of stress and aging: The glucocorticoid cascade hypothesis. *Endocr Rev.* (1986) 7:284–301. doi: 10.1210/edrv-7-3-284
58. Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: The impact of stress and glucocorticoids on glutamate transmission. *Nat Rev Neurosci.* (2012) 13:22–37. doi: 10.1038/nrn3138
59. Johannsen S, Duning K, Pavenstadt H, Kremerskothen J, Boeckers TM. Temporal-spatial expression and novel biochemical properties of the memory-related protein KIBRA. *Neuroscience* (2008) 155:1165–73. doi: 10.1016/j.neuroscience.2008.06.054
60. Kremerskothen J, Plaas C, Buther K, Finger I, Veltel S, Matanis T, et al. Characterization of KIBRA, a novel WW domain-containing protein. *Biochem Biophys Res Commun.* (2003) 300:862–7. doi: 10.1016/S0006-291X(02)02945-5
61. Zhang L, Yang S, Wenmann DO, Chen Y, Kremerskothen J, Dong J. KIBRA: In the brain and beyond. *Cell Signal.* (2014) 26:1392–9. doi: 10.1016/j.cellsig.2014.02.023
62. Buther K, Plaas C, Barnekow A, Kremerskothen J. KIBRA is a novel substrate for protein kinase Czeta. *Biochem Biophys Res Commun.* (2004) 317:703–7. doi: 10.1016/j.bbrc.2004.03.107
63. Sacktor TC, Hell JW. The genetics of PKM $\zeta$  and memory maintenance. *Sci Signal.* (2017) 10:eaa02327. doi: 10.1126/scisignal.aao2327
64. Pastalkova E, Serrano P, Pinkhasova D, Wallace E, Fenton AA, Sacktor TC. Storage of spatial information by the maintenance mechanism of LTP. *Science* (2006) 313:1141–4. doi: 10.1126/science.1128657
65. Yoshihama Y, Chida K, Ohno S. The KIBRA-aPKC connection: A potential regulator of membrane trafficking and cell polarity. *Commun Integr Biol.* (2012) 5:146–51. doi: 10.4161/cib.18849

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Stepan, Anderzhanova and Gassen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.